Leo Pharma partners with Vipergen on dermatology drug discovery

The two firms hope to find new treatments for dermatological diseases using Vipergen’s drug discovery platform.


Dermatology firm Leo Pharma has entered a partnership with Danish firm Vipergen, which provides small molecule drug discovery services based on DNA-encoded library (DEL) technologies, according to a press release.

The two aim to discover multiple new treatments for dermatology indications. Vipergen will bring its DEL technology to the collaboration while Leo Pharma will be in charge of choosing any potential ”hits” for subsequent development.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs